Patents by Inventor Francis J Carr

Francis J Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210015895
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: June 18, 2020
    Publication date: January 21, 2021
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • Patent number: 10722551
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 28, 2020
    Assignee: Proclara Biosciences, Inc.
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • Publication number: 20200172616
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 4, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Patent number: 10370448
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 6, 2019
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Publication number: 20180371084
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 27, 2018
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Publication number: 20180371066
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragments are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Application
    Filed: March 23, 2018
    Publication date: December 27, 2018
    Inventors: Tim WEST, Diljeet S. Athwal, Timothy D. JONES, Francis J. CARR, Robert George Edward HOLGATE
  • Publication number: 20180207231
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: December 2, 2015
    Publication date: July 26, 2018
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G.E. Holgate, Timothy D. Jones
  • Patent number: 10011656
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 3, 2018
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Patent number: 9957317
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 1, 2018
    Assignee: C2N Diagnostics, LLC
    Inventors: Tim West, Diljeet S. Athwal, Timothy D. Jones, Francis J. Carr, Robert George Edward Holgate
  • Publication number: 20180016340
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: February 22, 2017
    Publication date: January 18, 2018
    Inventors: David CLEMMONS, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon Willam Keen
  • Patent number: 9587024
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 7, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Publication number: 20170058024
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Application
    Filed: September 6, 2016
    Publication date: March 2, 2017
    Inventors: Tim West, Diljeet S. Athwal, Timothy D. Jones, Francis J. Carr, Robert George Edward Holgate
  • Publication number: 20160137731
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: August 10, 2015
    Publication date: May 19, 2016
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Publication number: 20150259422
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 17, 2015
    Inventors: David CLEMMONS, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Patent number: 9102727
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 11, 2015
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Patent number: 9102736
    Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: August 11, 2015
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
  • Patent number: 9073996
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 7, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Publication number: 20150018526
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Application
    Filed: April 1, 2014
    Publication date: January 15, 2015
    Applicant: Merck Patent GmbH
    Inventors: Matthew BAKER, Francis J. CARR, Koen HELLENDOORN, Jeannick CIZEAU, Glen C. MACDONALD, Joycelyn ENTWISTLE, Denis G. BOSC, Nicholas R. GLOVER
  • Patent number: 8758757
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 24, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Patent number: 8716234
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 6, 2014
    Assignee: Merck Patent GmbH
    Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover